SANTA CLARA, Calif.–(BUSINESS WIRE)–Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the appointment of medical device expert Jeryl (“Jeri”) Hilleman to the company’s Board of Directors. “We are thrilled to welcome Jeri to our team and look forward to leveraging her deep expertise with high-growth […]
Financial
HeartBeam Appoints Rich Ferrari and Marga Ortigas-Wedekind to its Board of Directors
Industry Veterans Join Diagnostic mHealth Company SANTA CLARA, Calif., Jan. 7, 2020 /PRNewswire/ — HeartBeam, Inc., a cardiac diagnostic mHealth company, today announced it has expanded its Board of Directors adding two seasoned professionals, Rich Ferrari, a Silicon Valley venture capitalist and Marga Ortigas-Wedekind, a marketing executive in the cardiac monitoring space. Rich Ferrari co-founded De […]
Proximo Medical Named Commercialization Partner for CeloNova BioSciences, Inc. in Select U.S. Markets
CeloNova BioSciences’ COBRA PzF NCS is world’s first and only non drug-eluting, nanocoated coronary stent; specifically designed to treat PCI patients at high risk for bleeding complications CASTLE PINES, Colo., Jan. 8, 2020 /PRNewswire/ — Today Proximo Medical, LLC, a fractional commercial organization for start-up medical device technologies and established medical device companies […]
Ra Medical Systems Names Dr. Chris Folk Vice President of Engineering
CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces the appointment of Chris Folk, PhD, as Vice President of Engineering, effective January 13, 2020. With more than 20 years of engineering experience primarily in […]
Zynex Expands Corporate Headquarters to Accommodate Growth
ENGLEWOOD, Colo., Jan. 7, 2020 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it has signed an addendum to its corporate headquarters building lease expanding the footprint to 86,000 square […]
Amarin Provides Update to Preliminary 2019 Results and Further Details on 2020 Outlook
Unaudited Full-Year 2019 Net Total Revenue Estimated At or Slightly Above Upper-End of Prior Guidance of $410 to $425 Million U.S. Sales Force Expansion On-Track for Doubling to 800 Sales Professionals in Early 2020 Full-Year 2020 Net Total Revenue Guidance Reiterated at $650 to $700 Million, Predominately from U.S. Sales […]
AngioDynamics Reports Fiscal 2020 Second Quarter Financial Results
Fiscal 2020 Second Quarter Highlights Net sales of $70.0 million, flat compared to the prior-year quarter Gross margin increased 140 basis points year over year to 59.3% GAAP loss per share of $0.07; adjusted earnings per share of $0.06 Announces the acquisition of C3 Wave PICC tip location system subsequent to quarter end […]
Continued Success of Novoheart to Receive R&D Grants: Innovation Technology Fund for Developing Smart Cardiac Screening Technologies
Grant will fund advanced R&D and incorporation of artificial intelligence (AI) technology to accelerate drug development using Novoheart’s bio-engineered human heart chambers and tissues The resulting advancements expected to increase scale and capabilities of Novoheart’s MyHeart™ Platform and expand commercialization opportunities for Novoheart’s market-leading technologies VANCOUVER, British Columbia, Jan. 07, […]
Tom Sheehy Joins Preventice Leadership Team as EVP and Chief Commercial Officer
MINNEAPOLIS, Jan. 6, 2020 /PRNewswire/ — Preventice Solutions announced today the appointment of Tom Sheehy as executive vice president (EVP) and chief commercial officer (CCO). In this role, Sheehy will lead the Preventice commercial organization, including sales, marketing and product management. Sheehy joins Preventice from Medtronic, where he recently served as a senior area sales […]
Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran
Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL cholesterol (LDL-C) goal and remain at increased risk of cardiovascular events1 The Medicines Company submitted the New Drug Application (NDA) for inclisiran to the FDA […]



